Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when REGN reports first-quarter results on April 29.

Regeneron signs $3 billion deal with FUJIFILM to expand biologics manufacturing in North Carolina, boosting U.S. capacity and ...

As previously reported, Cantor Fitzgerald analyst Carter Gould upgraded Regeneron (REGN) to Overweight from Neutral with a price target of ...

The complete response letter did not identify any issues with the safety or efficacy of Eylea HD, Regeneron officials said.

The FDA issued a complete response letter for a supplemental biologics license application, in which it did not approve ...

Oppenheimer keeps an Outperform rating on Regeneron (REGN) with a $925 price target after the FDA denied the company’s attempt to extend the ...

The FDA did not agree with a supplemental Biologics License Application for the addition of extended dosing intervals of up ...

The FDA has sent Regeneron a complete response letter, rejecting its bid to stretch the administration of high-dose Eylea ...

The FDA made two de­ci­sions on Re­gen­eron’s best-sell­ing drugs Fri­day, hand­ing down one ap­proval and one re­jec­tion.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter ...

The FDA told Regeneron in a complete response letter that while it didn't identify any issues with the safety or efficacy of the drug in its approved indications and dosing regimens, the agency didn't ...

Regulatory action was based on data from the Phase III QUASAR trial, which demonstrated that Eylea HD dosed every eight weeks ...